"We Envision Growth Strategies Most Suited
to Your Business"
The global prothrombin complex concentrate (PCC) market size is projected to reach USD 1,604.9 million by 2027 on account of growing preference for 4-factor PCC among patients, observes Fortune Business Insights™ in its report, titled “Prothrombin Complex Concentrate (PCC) Market Size, Share & COVID-19 Impact Analysis, By Product (3-factor PCC and 4-factor PCC), By Application (Acquired Coagulation Factor Deficiency and Congenital Coagulation Factor Deficiency), By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics and Others), and Regional Forecast, 2020-2027”. As per the report, the market value stood at USD 695.3 million in 2019 and is expected to exhibit a CAGR of 10.6% from 2020 to 2027.
The PCC market growth is expected to accelerate during 2020 owing to the outbreak of the COVID-19 pandemic. Pharmaceutical companies are reporting a swift change in consumer towards plasma-derived therapies, prompting these companies to ramp up their production and supply capacity of these treatments.
Takeda Successfully Acquires Shire plc, Becomes Global Leader in Biopharmaceuticals
Strategic acquisitions have become commonplace in the market for prothrombin complex concentrate. Leading this trend is the Japanese pharmaceutical bigwig, Takeda Pharmaceutical, which completed its takeover of the US-based biopharmaceutical specialist, Shire plc, in January 2019. The acquisition positions Takeda as global giant in biopharmaceutical research, especially in the domain of rare diseases. Furthermore, this move enlarges the company’s footprint in North America as well as in East Asia, allowing it to market and distribute its innovative PCC therapies in these regions. Lastly, the takeover augments Takeda’s R&D capabilities in rare diseases, neuroscience, gastroenterology, and oncology.
To get a detailed report summary and research scope of this market, click here:
Adverse Side Effects Associated with Warfarin to Stoke PCC Adoption
Warfarin is a commonly prescribed medication to inhibit formation of blood clots that can potentially lead to stroke or heart attack. However, imbalanced, unnecessary, and excessive prescription or consumption of this drug can trigger internal bleeding and can, in turn, further hamper the natural blood clotting process. Some of the major side effects of warfarin include joint pain and swelling, unexplained bruising on the body, vomiting blood, unusually heavy menstrual bleeding, and severe headache along with vision dysfunction. Prothrombin complex concentrate is a plasma-based therapy indicated to prevent bleeding in patients having impaired blood clotting mechanisms. This therapy has proven to be highly efficient in managing warfarin-induced bleeding in patients and as warfarin prescriptions increase, the demand for PCC is likely to rise commensurately.
Key Players to Engage in Tactical Takeovers to Expand Market Footprint
Some of the major players in the market for prothrombin complex concentrate, which are extremely limited in number, are increasingly entering into takeover deals to deepen their foothold regionally as well as globally. Improved access to new regions, along with the opportunities to establish strong distribution and sales network, is prompting these companies to massively invest in acquisition ventures. Moreover, the on-going COVID-19 pandemic is proving lucrative for the market players as the uptake of plasma-based therapies is skyrocketing across the globe.
Industry Development:
List of Companies Profiled in this Market Report:
Further Report Findings:
Table of Segmentation:
ATTRIBUTE | DETAILS |
Study Period | 2016-2027 |
Base Year | 2019 |
Forecast Period | 2020-2027 |
Historical Period | 2016-2018 |
Unit | Value (USD million) |
Segmentation | By Product Type
|
By Application
| |
By End User
| |
By Geography
|